BioMedNewsBreaks

MondaySep 12, 2022 12:24 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters into $6M Securities Purchase Agreement

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, has announced a private placement agreement with two healthcare-focused institutional investors. The agreement calls for the issuance and sale of 691,245 of INM common shares; the shares will be sold at a purchase price of $8.68 per share in a private placement priced according to Nasdaq guidelines. According to the announcement, InMed will also issue unregistered preferred investment options that will allow investors in the offering to purchase more than 1.3 million common shares. The company noted that it anticipates gross proceeds from the placement,…

Continue Reading

FridaySep 09, 2022 10:09 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Update on Company Objectives and Programs

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids and cannabinoid analogs, is reporting an update on the company’s research/development and commercial activities. According to the update, the company is working to complete enrollment in a phase 2 clinical program in epidermolysis bullosa (‘EB’) by the end of 2023, to advance its R&D efforts on a preclinical drug candidate in ocular disease and to investigate the potential of proprietary cannabinoid analogs in targeting specific diseases. The update included an observation that market demand for INM’s BayMedica naturally occurring cannabinoids is not progressing as anticipated,…

Continue Reading

ThursdaySep 08, 2022 1:40 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) on Leading Edge of Psilocybin Research

Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions. The company is on the leading edge of a transformation that has seen the status of psilocybin evolve as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. “After a flurry of research in the 1950s and 1960s, psilocybin and all other psychedelics were abruptly banned, partly in response to their embrace by the counterculture. Following the 1971 United Nations Convention on Psychotropic Substances, psilocybin was classed in the U.S.…

Continue Reading

WednesdaySep 07, 2022 1:52 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright 24th Annual Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its CEO John Climaco will present at the H.C. Wainwright 24th Annual Global Investment Conference. The event is being held in New York, New York, and virtually on Sept. 12-14, 2022. A video webcast of the presentation will be accessible for viewing on-demand beginning at 7:00 a.m. ET on Sept. 12 for those registered for the event. The webcast will also be available on the Events page of the company’s website,…

Continue Reading

TuesdaySep 06, 2022 12:33 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Secures FDA and Health Canada Approval for Phase 2 Trial of FSD201

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced its receipt of a “Study May Proceed” letter for the Investigational New Drug (“IND”) application from the U.S. Food and Drug Administration (“FDA”) and “Notice of Authorization” from Health Canada for its phase 2 clinical trial of FSD201. The trial will study the safety and efficacy of FSD201 in patients with chronic widespread musculoskeletal nociplastic pain associated with idiopathic mast cell activation syndrome. “We are delighted to…

Continue Reading

WednesdayAug 31, 2022 12:32 pm

BioMedNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Marks Final Development Milestone

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved the milestone identified as Y2, Q4(ii) as contemplated by the terms of a contribution agreement dated Dec. 4, 2020, among Cybin, Cybin Corp., Cybin US Holdings Inc. (the “acquiror”), a wholly controlled subsidiary of Cybin, and all of the previous shareholders of Adelia. “This final development milestone marks the completion of a detailed series of goals set between Cybin and Adelia almost two years ago. Our combined teams have executed…

Continue Reading

TuesdayAug 30, 2022 10:48 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a clinical milestone: the first two participants in its phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder (“MDD”) have been dosed. According to the announcement, CYB003 is the first-ever novel psilocybin analog to enter clinical development. The company is conducting a randomized, double-blind, placebo-controlled study evaluating people with moderate to severe MDD in which participants will receive two administrations (placebo/active and active/active) with a response assessed at week 3 after first dose and at week 6 after second dose. “To…

Continue Reading

MondayAug 29, 2022 12:19 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured in NeurologyLive(R) Article

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured in a recent NeurologyLive(R) article. The piece, titled “Concussion Treatment PRV-002 Demonstrates Safe, Tolerable Profile in Phase 1 Trial” and written by Marco Meglio, discusses positive results from a multiday ascending dose trial. “In cohort 1 of the multiday ascending dose (‘MAD’) trial, eight healthy human volunteers were randomly assigned 1:1 to 1 dose of PRV-003 or placebo for five consecutive days,” the article reads. “Evaluated by the Safety Review Committee, no serious adverse events were recorded, and all patients demonstrated normal vital signs, electrocardiogram…

Continue Reading

FridayAug 26, 2022 1:09 pm

BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Poised to Offer First-of-Its-Kind Responsiveness to Concussion

Odyssey Health (OTC: ODYY), a medical device innovator and biopharmaceutical product developer, has been advancing a proposed solution for brain injury from concussive forces. “Odyssey Health’s novel compound PRV-002 is the combination of a device and the medicine it delivers to treat concussions during the first moments after their occurrence, before permanent or long-term damage can set in. No U.S. Food and Drug Administration (‘FDA’)-approved drug treatment exists for concussion, and medical providers are generally left to rely on prescribed rest to help patients recover. But if Odyssey’s product can be established as safe and effective, it will open doors…

Continue Reading

ThursdayAug 25, 2022 3:44 pm

BioMedNewsBreaks – BioLife Sciences Inc. (BLFE) Expands with Focus on Disruptive Hemp Products

BioLife Sciences (OTC: BLFE) has announced that it will be expanding the scope of its orthomolecular medicine and natural health products division, with a specific focus on hemp products. According to the update, the company will focus on new and innovative product infusions centered around North American-grown, third-party tested industrial hemp with the intention to provide consumers with an array of new and more effective options. “We are so thrilled that BioLife will be focusing on this stream of business focusing on products in the marketplace, which are not only disruptors, but that are beneficial and useful products for consumers…

Continue Reading